Ectonucleotidase expression on T-helper cells as a response assessment tool to immune-checkpoint therapy in head and neck cancers
-
Published:2024-06
Issue:
Volume:10
Page:100401
-
ISSN:2772-9060
-
Container-title:Oral Oncology Reports
-
language:en
-
Short-container-title:Oral Oncology Reports
Author:
Arvind B.ORCID,
Puvvula Praneetha,
Thakur Shalini,
Subash Anand,
Rao VishalUS.
Reference13 articles.
1. Platinumbased chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008
2. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up;Licitra;Ann Oncol,2009
3. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic headandneck squamous cell carcinoma (KEYNOTE040): a randomised, openlabel, phase 3 study;Cohen;Lancet,2019
4. KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC);Burtness;Ann Oncol,2018
5. Anti–PD-1 and anti–PD-L1 in head and neck cancer: a network meta-analysis;Botticelli;Front Immunol,2021